NDATOPICALCREAM
Approved
Jan 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
TRI-LUMA (fluocinolone acetonide, hydroquinone, and tretinoin) by Galderma is corticosteroid hormone receptor agonists [moa]. First approved in 2002.
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRI-LUMA is a fixed-dose combination topical cream containing fluocinolone acetonide (corticosteroid), hydroquinone (depigmenting agent), and tretinoin (retinoid) approved in 2002. It is indicated for melasma and other hyperpigmentation disorders. The formulation works through corticosteroid receptor agonism combined with melanin suppression and skin cell turnover enhancement.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30), suggesting brand team may be in transition or focused on market defense strategies.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma
Started Jan 2008
56 enrolled
Melasma
Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma
Started Nov 2006
20 enrolled
Melasma
Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma
Started Nov 2006
340 enrolled
Melasma
Career Relevance
TRI-LUMA offers limited new job creation due to LOE approaching and zero linked postings, making it a stable but non-growth career opportunity. Roles focus on defending market share, managing channel relationships, and preparing for generic competition rather than growth initiatives.
Worked on TRI-LUMA at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.